What is new in management of Takayasu arteritis?

Direskeneli, 2011, Assessment of disease activity and progression in Takayasu's arteritis, Clin Exp Rheumatol, 29, S86 Alibaz Oner, 2015, Recent advances in Takayasu's arteritis, Eur J Rheumatol, 1, 24, 10.5152/eurjrheumatol.2015.0060 Alibaz-Oner, 2016, Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up, Clin Exp Rheumatol, 34, S73 Keser, 2014, Management of Takayasu arteritis: a systematic Review, Rheumatology, 53, 793, 10.1093/rheumatology/ket320 Saruhan Direskeneli, 2013, Identification of multiple genetic susceptibility loci in Takayasu arteritis, Am J Hum Genet, 93, 298, 10.1016/j.ajhg.2013.05.026 de Souza, 2016, Leflunomide in Takayasu arteritis – A long term observational study, Rev Bras Reumatol Engl Ed., 56, 371, 10.1016/j.rbr.2015.09.007 Kazibudzki, 2016, New endovascular techniques for treatment of life-threatening Takayasu arteritis, Adv Interv Cardiol, 12, 171, 10.5114/aic.2016.59369 Spacek, 2012, Takayasu arteritis: use of drug-eluting stent and balloon to treat recurring carotid restenosis, J Invasive Cardiol, 24, E190, 10.1111/j.1540-8183.2011.00694.x de Souza, 2012, Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study, Scand J Rheumatol, 41, 227, 10.3109/03009742.2011.633553 Hoffman, 2004, Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis, Arthritis Rheum, 50, 2296, 10.1002/art.20300 Molloy, 2008, Antitumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up, Ann Rheum Dis, 67, 1567, 10.1136/ard.2008.093260 Schmidt, 2012, Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up, Arthritis Care Res (Hoboken), 64, 1079 Clifford, 2014, Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies, Curr Opin Rheumatol, 26, 7, 10.1097/BOR.0000000000000004 Novikov, 2013, Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature, Clin Rheumatol, 32, 1827, 10.1007/s10067-013-2380-6 Mekinian, 2015, Efficacy of biological targeted treatments in Takayasu Arteritis: multicenter, retrospective study of 49 patients, Circulation, 32, 1693, 10.1161/CIRCULATIONAHA.114.014321 Serra, 2014, Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis, J Pharmacol Pharmacother, 5, 193, 10.4103/0976-500X.136101 Osman, 2011, Takayasu's arteritis progression on anti-TNF biologics: a case series, Clin Rheumatol, 30, 703, 10.1007/s10067-010-1658-1 Saadoun, 2015, Th1 and Th17 cytokines drive inflammation in Takayasu arteritis, Arthritis Rheumatol, 67, 1353, 10.1002/art.39037 Kong, 2016, The critical role of IL-6 in the pathogenesis of Takayasu arteritis, Clin Exp Rheumatol, 34, S21 Renauer, 2015, Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a genome-wide association study, Arthritis Rheumatol, 67, 1361, 10.1002/art.39035 Nishimoto, 2008, Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody, Arthritis Rheum, 58, 1197, 10.1002/art.23373 Goel, 2013, Rapid control of disease activity by tocilizumab in 10 “difficult-to-treat” cases of Takayasu arteritis, Int J Rheum Dis, 16, 754, 10.1111/1756-185X.12220 Loricera, 2014, Tocilizumab in refractory aortitis: study on 16 patients and literature review, Clin Exp Rheumatol, 32, S79 Canas, 2014, Efficacy and safety of antiinterleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis, J Clin Rheumatol, 20, 125, 10.1097/RHU.0000000000000098 Schiavon, 2014, Takayasu arteritis and NYHA III/IV idiopathic cardiomiopathy: tocilizumab proves effective and safe, Joint Bone Spine, 81, 278, 10.1016/j.jbspin.2013.11.008 Youngstein, 2014, Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-alpha and IL-6 receptor targeted therapies in refractory Takayasu arteritis, Clin Exp Rheumatol, 32, S11 Tombetti, 2013, Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center, J Rheumatol, 40, 2047, 10.3899/jrheum.130536 Bredemeier, 2012, One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab, Clin Exp Rheumatol, 30, S98 Abisror, 2013, Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review, Autoimmun Rev, 12, 1143, 10.1016/j.autrev.2013.06.019 Osman, 2015, Tocilizumab for treating Takayasu's Arteritis and associated stroke: a case series and updated review of the literature, J Stroke Cerebrovasc Dis, 24, 1291, 10.1016/j.jstrokecerebrovasdis.2015.01.032 Salvarani, 2012, Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-blockers, Clin Exp Rheumatol, 30, S90 Salvarani, 2012, Tocilizumab: a novel therapy for patients with large-vessel vasculitis, Rheumatology (Oxford), 51, 151, 10.1093/rheumatology/ker296 Unizony, 2012, Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica, Arthritis Care Res (Hoboken), 64, 1720, 10.1002/acr.21750 Pazzola, 2016, Biotherapies in large vessel vasculitis, Rev Med Interne, 37, 274, 10.1016/j.revmed.2015.08.012 Xenitidis, 2013, Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis, Rheumatology (Oxford), 52, 1729, 10.1093/rheumatology/ket107 Youngstein, 2013, Interleukin 6 targeting in refractory Takayasu arteritis: serial noninvasive imaging is mandatory to monitor efficacy, J Rheumatol, 40, 1941, 10.3899/jrheum.131232 Arita, 2015, Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis, Int J Cardiol, 187, 319, 10.1016/j.ijcard.2015.03.399 Koster, 2016, Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis, Curr Opin Rheumatol, 28, 211, 10.1097/BOR.0000000000000265 Tombetti, 2013, Management options for Takayasu arteritis, Expert Opin Orphan Drugs., 1, 685, 10.1517/21678707.2013.827570 Inder, 2000, Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions, Cardiovasc Surg, 8, 141, 10.1016/S0967-2109(99)00100-3 Nishino, 2010, Serum levels of BAFF for assessing the disease activity of Takayasu arteritis, Clin Exp Rheumatol, 28, 14 Hoyer, 2012, Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab, Ann Rheum Dis, 71, 75, 10.1136/ard.2011.153007 Silverman, 2003, Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy, Arthritis Rheum, 48, 1484, 10.1002/art.10947 Galarza, 2008, Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?, Clin Rev Allergy Immunol, 34, 124, 10.1007/s12016-007-8028-z Ernst, 2012, Remission achieved in refractory advanced Takayasu arteritis using rituximab, Case Rep Rheumatol, 2012, 406963 Caltran, 2014, Two Takayasu arteritis patients successfully treated with rituximab, Clin Rheumatol, 33, 1183 Terao, 2013, Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population, Am J Hum Genet, 93, 289, 10.1016/j.ajhg.2013.05.024 Piggott, 2011, Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis, Circulation, 123, 309, 10.1161/CIRCULATIONAHA.110.936203 Lally, 2015, Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis, Rheumatology (Oxford), 54, 554, 10.1093/rheumatology/keu364 Terao, 2015, Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application, Scand J Rheumatol, 27, 1 Saadoun, 2012, Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience, Circulation, 125, 813, 10.1161/CIRCULATIONAHA.111.058032 Kim, 2012, Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis, J Vasc Surg, 55, 693, 10.1016/j.jvs.2011.09.051 Perera, 2013, Takayasu arteritis: criteria for surgical intervention should not be ignored, Int J Vasc Med, 2013, 618910 Ham, 2011, Disease progression after initial surgical intervention for Takayasu arteritis, J Vasc Surg, 54, 1345, 10.1016/j.jvs.2011.04.044 Wrotniak, 2013, Long-term experience in patients undergoing endovascular revascularization procedures for symptomatic Takayasu arteritis, J Rare Cardiovasc Dis, 1, 8 Horie, 2011, Restenosis after endovascular PTA/stenting for supra-aortic branches in Takayasu aortitis: report of three cases and review of the literature, Acta Neurochir (Wien), 153, 1135, 10.1007/s00701-010-0932-y de Souza, 2010, Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis, Circ J, 74, 1236, 10.1253/circj.CJ-09-0905 Visona, 2009, Antithrombotic treatment before and after peripheral artery percutaneous angioplasty, Blood Transfus, 7, 18 Park, 2006, Postinterventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis, Rheumatology, 45, 600, 10.1093/rheumatology/kei245 Langford, 2017, A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis, Arthritis Rheumatol, 69, 846, 10.1002/art.40037